Background: Retesting for Human epidermal growth factor receptor-2 (HER2) in post-neoadjuvant therapy resection is variable. and data is conflicting regarding the prognostic significance of changes in HER2 expression pre and post therapy. Methods: We identified 104 patients with localized HER2 IHC 3+ breast cancer who received neoadjuvant trastuzumab(T)/pertuzumab(P) containing chemot... https://www.plataformalabcc.com/product-category/womens-apparel/